Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 [tasimelteon] and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia

X
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 [tasimelteon] and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2014

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Acronyms JET5
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 20 May 2009 Results presented at APA 2009.
    • 02 Dec 2008 Results published in the Lancet.
    • 17 Nov 2006 Status change

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top